Toward a prostate cancer precision medicine.

Area of Science:

• Oncology
• Genomics
• Translational Medicine

Background:

• Precision cancer medicine aims to personalize treatment by integrating clinical and genomic data.
• Current focus includes matching Food and Drug Administration-approved drugs to patient tumors.
• Beyond treatment selection, precision medicine offers potential for predicting disease progression risk.

Purpose of the Study:

• To explore the role of precision medicine in enhancing cancer care efficiency and effectiveness.
• To highlight the development of improved molecular biomarkers for cancer.
• Specifically, to address the need for biomarkers in prostate cancer to distinguish indolent from aggressive disease.

Main Methods:

• Integration of clinical and genomic datasets.
• Analysis of existing Food and Drug Administration-approved cancer drugs for targeted therapy.
• Biomarker discovery and validation methodologies.

Main Results:

• Precision medicine facilitates more efficient cancer treatment strategies.
• Potential for improved predictive molecular biomarkers in oncology.
• Identified a critical need for specific biomarkers in prostate cancer.

Conclusions:

• Precision cancer medicine promises improved patient outcomes through data integration.
• Biomarker development is crucial for personalized risk assessment and treatment stratification.
• Distinguishing indolent from aggressive prostate cancer is a key objective for biomarker research.